ArticleMovement disorders clinical practice2026
The Mild Behavioral Impairment Checklist for Parkinson's Disease: An Ancillary Instrument in Cognitive Assessment.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elucidating the Neurobiological Underpinnings of Mild Behavioral Impairment in Tauopathies: Clinical and Molecular Insights.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMild behavioral impairment (MBI) is a syndrome characterized by the later-life onset of neuropsychiatric symptoms (NPS) and serves as a potential marker for dementia. In Parkinson's disease (PD), MBI has been associated with worse cognition, cortical atrophy, and altered connectivity. Unlike existing instruments that assess NPS in PD, the MBI Checklist (MBI-C) leverages sustained behavioral changes to identify patients at risk of cognitive impairment and neurodegeneration. The 34-item MBI-C has yet to be validated in PD.
objectiveThis study assesses the MBI-C's psychometric properties in a multicenter Canadian PD sample and proposes a revised version optimized for PD.
methodsA total of 406 PD patients from the Canadian Open Parkinson Network were assessed with the MBI-C to investigate its construct validity. Additional evaluations, including the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Neuropsychiatric Inventory (NPI), and Montreal Cognitive Assessment (MoCA), were implemented to examine the concurrent and criterion validities of the checklist.
resultsThe original MBI-C exhibited considerable floor effects (24.9%). Exploratory factor analysis revealed a 5-factor 24-item MBI-C as consistent for PD (Cronbach's α = 0.856). All intrafactor correlations were statistically significant (P < 0.05), and convergent validity was found to be higher than divergent validity. Moreover, the MBI-C demonstrated moderate concurrent validity with the NPI (intraclass correlation coefficient [ICC]: 0.633, P < 0.001). The cutoff score associated with cognitive impairment on the revised instrument was 6|7.
conclusionsCompared to the original version, the revised MBI-C exhibited enhanced psychometric properties for measuring MBI in PD. It also demonstrated acceptable specificity when related to cognitive impairment. Future psychometric research should focus on capturing the subtlest manifestations of MBI in PD, examining patient-caregiver concordance, and addressing predictive validity for cognitive decline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.